$2.90▴ 5.45%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-140.50MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
-39.2%year over year
Weak
Revenue is contracting year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Editas Medicine, Inc. is pre-profit. It is still burning cash while pre-profit. Revenue is contracting year over year.
Key numbers
Valuation
EPS (TTM)$-1.17
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin-281.6%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$38.69M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days1 article
0 bullish1 neutral0 bearish
Lyora Therapeutics Launches With Seed Funding to Propel Its Biologically Validated Pipeline of Genetic Medicines to Treat Inherited Retinal Diseases
Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth Forecast
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.